JP2021532126A5 - - Google Patents

Info

Publication number
JP2021532126A5
JP2021532126A5 JP2021503770A JP2021503770A JP2021532126A5 JP 2021532126 A5 JP2021532126 A5 JP 2021532126A5 JP 2021503770 A JP2021503770 A JP 2021503770A JP 2021503770 A JP2021503770 A JP 2021503770A JP 2021532126 A5 JP2021532126 A5 JP 2021532126A5
Authority
JP
Japan
Prior art keywords
composition according
composition
administration
placebo
months
Prior art date
Application number
JP2021503770A
Other languages
English (en)
Japanese (ja)
Other versions
JP7541505B2 (ja
JPWO2020023530A5 (https=
JP2021532126A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/043067 external-priority patent/WO2020023530A2/en
Publication of JP2021532126A publication Critical patent/JP2021532126A/ja
Publication of JPWO2020023530A5 publication Critical patent/JPWO2020023530A5/ja
Publication of JP2021532126A5 publication Critical patent/JP2021532126A5/ja
Priority to JP2024077300A priority Critical patent/JP2024112859A/ja
Application granted granted Critical
Publication of JP7541505B2 publication Critical patent/JP7541505B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021503770A 2018-07-24 2019-07-23 アルツハイマー病の治療及び予防方法 Active JP7541505B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024077300A JP2024112859A (ja) 2018-07-24 2024-05-10 アルツハイマー病の治療及び予防方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862702659P 2018-07-24 2018-07-24
US62/702,659 2018-07-24
US201862749614P 2018-10-23 2018-10-23
US62/749,614 2018-10-23
US201962824162P 2019-03-26 2019-03-26
US62/824,162 2019-03-26
US201962846902P 2019-05-13 2019-05-13
US62/846,902 2019-05-13
US201962874684P 2019-07-16 2019-07-16
US62/874,684 2019-07-16
PCT/US2019/043067 WO2020023530A2 (en) 2018-07-24 2019-07-23 Methods of treatment and prevention of alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024077300A Division JP2024112859A (ja) 2018-07-24 2024-05-10 アルツハイマー病の治療及び予防方法

Publications (4)

Publication Number Publication Date
JP2021532126A JP2021532126A (ja) 2021-11-25
JPWO2020023530A5 JPWO2020023530A5 (https=) 2022-07-28
JP2021532126A5 true JP2021532126A5 (https=) 2022-07-28
JP7541505B2 JP7541505B2 (ja) 2024-08-28

Family

ID=67551415

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021503770A Active JP7541505B2 (ja) 2018-07-24 2019-07-23 アルツハイマー病の治療及び予防方法
JP2024077300A Pending JP2024112859A (ja) 2018-07-24 2024-05-10 アルツハイマー病の治療及び予防方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024077300A Pending JP2024112859A (ja) 2018-07-24 2024-05-10 アルツハイマー病の治療及び予防方法

Country Status (13)

Country Link
US (1) US20210324056A1 (https=)
EP (1) EP3826674A2 (https=)
JP (2) JP7541505B2 (https=)
KR (1) KR20210039402A (https=)
CN (2) CN118924896A (https=)
AU (1) AU2019309938B2 (https=)
BR (1) BR112021001272A2 (https=)
CA (1) CA3107370A1 (https=)
IL (3) IL310132B2 (https=)
MX (1) MX2021000778A (https=)
PH (1) PH12021500006A1 (https=)
TW (1) TW202019471A (https=)
WO (1) WO2020023530A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
KR20220156534A (ko) * 2020-03-20 2022-11-25 에자이 알앤드디 매니지먼트 가부시키가이샤 고농도 항-Aβ 프로토피브릴 항체 제형물 및 이의 사용 방법
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
WO2022035758A1 (en) * 2020-08-12 2022-02-17 The Cleveland Clinic Foundation Bace1 inhibitor treatment for suppressing cytokine storm
TW202300517A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
KR20240115910A (ko) * 2021-12-17 2024-07-26 에자이 알앤드디 매니지먼트 가부시키가이샤 항-아밀로이드 베타 원섬유 항체 및 항-타우 항체의 사용 방법
WO2023111618A1 (en) * 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
MX2024009492A (es) * 2022-02-02 2024-08-09 Eisai R&D Man Co Ltd Metodos de tratamiento mediante el uso del nivel de proteina tau fosforilada 181 (p-tau181).

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
AU2016208353B2 (en) * 2007-10-17 2017-07-20 Janssen Alzheimer Immunotherapy Immunotherapy regimes dependent on ApoE status
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
RU2476431C2 (ru) 2008-01-18 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Конденсированное производное аминодигидротиазина
PT2448968T (pt) 2009-06-29 2021-04-30 Bioarctic Ab ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL
JP2013521233A (ja) * 2010-02-25 2013-06-10 ヤンセン アルツハイマー イミュノセラピー Aβを標的とする免疫療法のPETモニタリング
CA2789963C (en) 2010-02-26 2019-09-03 Bioarctic Neuroscience Ab Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
US8426584B2 (en) 2011-01-21 2013-04-23 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
EP3166970B1 (en) * 2014-07-10 2021-03-10 BioArctic AB Improved a-beta protofibril binding antibodies
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
BR112018014762A2 (pt) * 2016-01-20 2018-12-26 Genentech Inc método de tratamento da doença de alzheimer (da) precoce
ES2939373T3 (es) * 2016-05-13 2023-04-21 Pasteur Institut Inhibición de los receptores de acetilcolina nicotínicos beta-2 para tratar la patología de la enfermedad de Alzheimer
TWI798751B (zh) * 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗-N3pGlu類澱粉β肽抗體及其用途
CN117244056A (zh) * 2016-10-27 2023-12-19 卫材研究发展管理有限公司 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物

Similar Documents

Publication Publication Date Title
JP2021532126A5 (https=)
JP2024112859A5 (https=)
JP6875454B2 (ja) Hivを治療するためのトール様受容体の調節因子
US9464096B2 (en) Therapeutic compounds
JP2013542194A5 (https=)
RU2016130056A (ru) Способы лечения кожной инфекции путем введения антагониста il-4r
MD3478712T2 (ro) Anticorpi peptidici beta amiloizi anti-N3pGlu și utilizări ale acestora
JP2022033868A5 (https=)
JP2017512193A5 (https=)
JP2006522830A5 (https=)
JP2013521303A5 (https=)
JP2018505882A5 (https=)
JP2020521797A5 (https=)
JP2020502261A5 (https=)
JPWO2020023530A5 (https=)
JP2015172060A5 (https=)
JP2021523138A5 (https=)
JP2021529766A5 (https=)
JP2012510814A5 (https=)
JP2022125248A (ja) 視神経脊髄炎スペクトル障害の治療に有用な組成物及び方法
JPWO2023019171A5 (https=)
JPWO2022081799A5 (https=)
CA3185105A1 (en) Cd-3 antibodies for the treatment of coronavirus
JP2020503318A5 (https=)
JPWO2023079485A5 (https=)